Angiox

>10%

Back pain (42%)

General pain (15%)

Nausea (15%)

Hemorrhage, minor (13.6%)

Headache (12%)

Hypotension (12%)

1-10%

Injection site pain (8%)

Insomnia (7%)

Pelvic pain (6%)

Hypertension (6%)

Anxiety (6%)

Vomiting (6%)

Bradycardia (5%)

Dyspepsia (5%)

Abdominal pain (5%)

Fever (5%)

Nervousness (5%)

Urinary retention (4%)

Hemorrhage, major (2.3%)

≥3g/dL fall in Hgb (1.9%)

TIMI minor bleeding (1.3%)

RBC transfusions (1.3%)

Postmarketing Reports

Pulmonary hemorrhage

Cardiac tamponade

INR increased

Mechanism of Action

Competitive, direct thrombin inhibitor; thrombin enables fibrinogen conversion to fibrin during the coagulation cascade; Inhibition of fibrinogen conversion to fibrin inhibits thrombus development

Inhibits both free and clot-bound thrombin and thrombin-induced platelet aggregation

Synthetic analog of hirudin

Pharmacokinetics

Half-Life: 25 min (normal renal function); 57 min (severe renal impairment)

Duration: ~ 1 hr after infusion discontinued

Protein Bound: Minimal

Clearance: 60-89 mL/min; Reduced in severe renal impairment

Metabolism: Blood proteases

Excretion: renal

Dialyzable: Yes